SCHEMBL29598

SCHEMBL29598

O=C(O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2C[S+]1[O-]

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 7/20 0.56
ABL1 P00519 2/20 0.56
IDE P14735 2/20 0.56
RIN1 Q13671 2/20 0.56
MEN1 O00255 1/20 0.56
LMNA P02545 1/20 0.56
PKM P14618 1/20 0.56
MAPK1 P28482 1/20 0.56
KMT2A Q03164 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
PPARG P37231 1/20 0.43
NR2E3 Q9Y5X4 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
HLCS P50747 6/20 0.36
CA12 O43570 3/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA9 Q16790 3/20 0.34
FOLH1 Q04609 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10171650 1.00 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL30508570 1.00 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL17752940 1.00 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL14562968 1.00 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL18924547 1.00 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL17761083 0.90 TDP1 (0.45) TDP1ABL1IDERIN1MEN1
SCHEMBL4959481 0.88 TDP1 (0.43) TDP1ABL1IDERIN1MEN1
SCHEMBL21516801 0.86 TDP1 (0.58) TDP1ABL1IDERIN1MEN1
SCHEMBL21488893 0.86 TDP1 (0.58) TDP1ABL1IDERIN1MEN1
SCHEMBL21488894 0.86 TDP1 (0.58) TDP1ABL1IDERIN1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4416303-A1 A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL Blink AG (DE) 2024-08-21 EP claimed
CN-118510909-A Microsphere comprising a first material and a second material 布林克公司 2024-08-16 CN claimed
US-20240084354-A1 MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST HONING BIOSCIENCES (FR) 2024-03-14 US claimed
WO-2024023009-A1 SYSTEM AND METHOD FOR MEASURING ORIENTATION OF AN OBJECT BASED ON IMU MARG ORIENTATION ESTIMATION MIMETIK UG (DE) 2024-02-01 WO claimed
EP-4284416-A1 ENGINEERED CPN1 CONSTRUCTS AND VARIANTS Vertex Pharmaceuticals Incorporated (US) 2023-12-06 EP claimed
EP-4244240-A1 MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST Honing Biosciences (FR) 2023-09-20 EP claimed
WO-2023154852-A1 ANTIBODY BARCODED BEADS AND USES THEREOF CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-08-17 WO claimed
EP-2552202-B1 METHODS AND COMPOSITIONS FOR WEIGHT LOSS SDG INC (US) 2023-07-26 EP claimed
WO-2023079140-A1 A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL BLINK AG (DE) 2023-05-11 WO claimed
EP-4177352-A1 A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL Blink AG (DE) 2023-05-10 EP claimed
WO-2000002051-A1 TRIFUNCTIONAL REAGENT FOR CONJUGATION TO A BIOMOLECULE DEPT. OF RADIATION ONCOLOGY, UNIVERSITY OF WASHINGTON (US) 2000-01-13 WO claimed
WO-2000002050-A1 TRIFUNCTIONAL REAGENT FOR CONJUGATION TO A BIOMOLECULE DEPARTMENT OF RADIATION ONCOLOGY, UNIVERSITY OF WASHINGTON (US) 2000-01-13 WO claimed
EP-0743956-A4 PRETARGETING METHODS AND COMPOUNDS NEORX CORP (US) 1999-03-24 EP claimed
US-5622249-A Conveyor belt scraper MORIN NORMAND J (CA) 1997-04-22 US claimed
EP-0743956-A1 PRETARGETING METHODS AND COMPOUNDS NeoRx (US) 1996-11-27 EP claimed
WO-1995015978-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-06-15 WO claimed
US-5108921-A Contacting living cell membrane with complex of biotin and derivatives and biologically functional molecules; modifying cell function PURDUE RESEARCH FOUNDATION (US) 1992-04-28 US claimed
EP-0088542-B1 SKIN TREATMENT COMPOSITION UNILEVER N.V. (NL) 1988-05-11 EP claimed
US-4529587-A Using biotin antagonist LEVER BROTHERS COMPANY (US) 1985-07-16 US claimed
EP-0088542-A2 Skin treatment composition UNILEVER N.V. (NL) 1983-09-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240084354-A1 MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST PHAX, SCAMP2, YIPF5 TDP1 2678/4885ABL1 4402/4885IDE 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.